Skip to main content
Clinical Trials/ISRCTN57761809
ISRCTN57761809CompletedNot Applicable

Effect of anti-tumour necrosis factor alpha (TNFa) therapy on endothelial function and other surrogate markers of cardiovascular disease in patients with rheumatoid arthritis

niversity of Dundee (UK)0 sites90 target enrollmentStarted: May 9, 2008Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
90

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Both males and females, 18 years old or over
  • 2. Fulfil the 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis
  • 3. No exposure to anti-TNFa drugs in the last 3 months
  • 4. Fulfil the National Institute for Clinical Excellence guidelines on the use of anti-TNFa drugs in rheumatoid arthritis* and be:
  • 4.1. About to start etanercept or adalimumab (treatment group)
  • 4.2. About to start methotrexate (control group)
  • * The patients in the control group must have had adequate therapeutic trial of at least one previous Disease Modifying Anti-Rheumatic Drug (DMARD) rather than two

Exclusion Criteria

  • 1. Previous cardiovascular or cerebrovascular event in the last 3 years
  • 2. Undergoing treatment for a cardiovascular risk factor except:
  • 2.1. Patients with hypertension on stable medication for the last 3 months
  • 2.2. Patients with hypercholesterolaemia on stable medication for the last 3 months

Investigators

Sponsor
niversity of Dundee (UK)

Similar Trials